Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Interventional, Single Arm, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-ACLF for the Treatment of Acute-on-Chronic Liver Failure (ACLF)

NCT03860155 is registered in ClinicalTrials.gov with RHEACELL GmbH & Co. KG as lead sponsor.

NCT NCT03860155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03860155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Interventional, Single Arm, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-ACLF for the Treatment of Acute-on-Chronic Liver Failure (ACLF)
Lead sponsor
RHEACELL GmbH & Co. KG
Phase
Phase 1/2
Overall status
Terminated
Start date
March 22, 2019
Completion date
March 26, 2021
Enrollment
5 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute-on-chronic liver failure